Explore ADC Therapeutics Technology and Cancer Drug Development

ADC Therapeutics focuses on antibody drug conjugates, commonly known as ADCs, which are medicines designed to combine targeted recognition with potent anticancer activity. An ADC generally contains an antibody, a linker, and a therapeutic payload. The antibody helps identify cells carrying a particular target, while the payload is intended to produce the desired biological effect after delivery into the target cell. ADC Therapeutics describes its platform as being focused on ADC development, particularly for hematologic malignancies.

Explore ADC Therapeutics Technology and Its Role in Cancer Research

ADC technology represents an approach to targeted drug delivery. Instead of relying only on medicines that circulate throughout the body, an ADC is designed to recognize a specific antigen on a cell. After binding, the complex can be internalized, allowing the payload to be released inside the cell.

Key elements involved in ADC development include:

• Target antibody: Recognizes a selected antigen present on cancer cells.
• Linker: Connects the antibody with the therapeutic payload and influences how the payload is released.
• Payload: Provides potent biological activity intended to damage or eliminate targeted cancer cells.
• Target selection: Researchers evaluate whether a target is sufficiently present on cancer cells and suitable for therapeutic development.
• Clinical evaluation: Candidate ADCs undergo studies to assess safety, pharmacokinetics, tolerability, and potential anticancer activity.

ADC Therapeutics' ZYNLONTA is a CD19 directed ADC. According to the company, once ZYNLONTA binds to a CD19 expressing cell, it is internalized and enzymes release its pyrrolobenzodiazepine payload. The payload can form DNA cross links that interfere with cellular division.

Learn About Cancer Drug Development and ADC Research

Cancer drug development involves several stages, beginning with laboratory research and progressing through preclinical testing and clinical trials. For ADCs, researchers must consider several interconnected factors, including target selection, antibody characteristics, linker stability, payload potency, drug distribution, and safety.

ADC Therapeutics continues to evaluate ZYNLONTA in different clinical settings. In June 2026, the company reported completion of enrollment in its LOTIS 7 Phase 1b trial evaluating ZYNLONTA with glofitamab in patients with relapsed or refractory diffuse large B cell lymphoma, with full data expected later in 2026. The company has also reported ongoing investigator initiated studies examining ZYNLONTA in additional B cell malignancies.

Other aspects of ADC drug development include:

• Preclinical research: Laboratory and animal studies help researchers understand biological activity and potential safety concerns.
• Clinical trials: Human studies evaluate appropriate dosing, safety, tolerability, pharmacokinetics, and potential efficacy.
• Combination research: ADCs may be investigated alongside other cancer therapies to understand whether combined treatment can provide additional therapeutic effects.
• Biomarker research: Identifying appropriate molecular targets can help researchers determine which patient populations may be suitable for a particular ADC.
• Regulatory development: Successful candidates require review of clinical and manufacturing data before broader use can be considered.

ADC Therapeutics has also reported development work involving additional ADC candidates and different molecular targets. Its research has included approaches involving exatecan based payloads and targets such as PSMA, while development programs can change as clinical and scientific evidence becomes available.

ADC Therapeutics illustrates how antibody drug conjugate technology is being applied to cancer drug development. By combining targeted antibodies with potent payloads, ADC research aims to develop therapies capable of delivering anticancer activity to selected cells. Continued laboratory research, clinical trials, biomarker studies, and regulatory evaluation remain important for determining the safety, effectiveness, and appropriate applications of these medicines. This information is provided for educational purposes only and does not constitute medical advice, treatment guidance, or a sales or service offering.